DOSE-ESCALATION OF DACARBAZINE COMBINED WITH INTERFERON ALPHA-2A, G-CSF AND ONDANSETRON IN PATIENTS WITH METASTATIC MELANOMA

To define the activity of an individually escalated dacarbazine (DTIC) dose combined with interferon-alpha-2a (IFN), granulocyte-colony stim ulating-factor (G-CSF) and ondansetron, 20 patients (pts) with metasta tic melanoma were treated with DTIC, ondansetron 8 mg iv, G-CSF300 mu g sc and IFN 9 MU sc. Treatment was performed every 21 days to a maxim um of 6 courses. DTIC dose was escalated with 250 mg/m(2) in case of a cceptable toxicity to 1250, 1500 and 1750 mg/m(2) in (projected/realiz ed), 14/19, 8/11 and 0/5 pts, respectively. Dose escalation prohibitin g toxicities were thrombocytopenia (10 pts), leukopenia (9 pts), and n ausea/vomiting (2 pts). Four partial remissions were observed, for a r esponse rate of 20% (95% confidence interval, 6 to 44%). Duration of r esponses was 1, 2, 3 and 3 months. Median overall survival was 8 month s.